Nishida Teruo, Chikama Tai-Ichiro, Morishige Naoyuki, Yanai Ryoji, Yamada Naoyuki, Saito Jun
Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Jpn J Ophthalmol. 2007 Nov-Dec;51(6):442-7. doi: 10.1007/s10384-007-0480-z. Epub 2007 Dec 21.
The loss of corneal sensation results in the development of persistent corneal epithelial defects. The combination of a substance P-derived peptide, phenylalanine -glycine-leucine-methionine (FGLM)-amide, and insulin-like growth factor 1 (IGF-1) stimulates corneal epithelial migration in vitro and corneal epithelial wound closure in vivo. The clinical efficacy of eye drops containing FGLM-amide and IGF-1 for the treatment of persistent epithelial defects in individuals with neurotrophic keratopathy was examined in a prospective open study.
Eleven patients with persistent corneal epithelial defects associated with neurotrophic keratopathy were treated for up to 28 days by the administration of eye drops containing FGLM-amide and IGF-1. The course of epithelial healing was monitored by slit-lamp examination, and visual acuity was measured before and after treatment.
Complete epithelial resurfacing was achieved in eight of the nine (89%) cases of persistent epithelial defects in the nine patients who received the full course of treatment. Epithelial defects had completely resurfaced in two of nine (22%) and five of nine (56%) cases within 1 and 2 weeks, respectively, after treatment initiation. No adverse effects of treatment were observed in any of the 11 patients.
Eye drops containing FGLM-amide and IGF-1 induced the rapid resurfacing of persistent epithelial defects in individuals with neurotrophic keratopathy.
角膜感觉丧失会导致持续性角膜上皮缺损的发生。一种源自P物质的肽，苯丙氨酸 - 甘氨酸 - 亮氨酸 - 甲硫氨酸（FGLM）-酰胺，与胰岛素样生长因子1（IGF-1）联合使用，可在体外刺激角膜上皮迁移，并在体内促进角膜上皮伤口愈合。在一项前瞻性开放性研究中，对含有FGLM-酰胺和IGF-1的眼药水治疗神经营养性角膜病变患者持续性上皮缺损的临床疗效进行了研究。
11例与神经营养性角膜病变相关的持续性角膜上皮缺损患者，接受含有FGLM-酰胺和IGF-1的眼药水治疗，最长治疗28天。通过裂隙灯检查监测上皮愈合过程，并在治疗前后测量视力。
在接受完整疗程治疗的9例患者中，9例持续性上皮缺损病例中有8例（89%）实现了上皮完全修复。治疗开始后1周内，9例中有2例（22%）上皮缺损完全修复；2周内，9例中有5例（56%）上皮缺损完全修复。11例患者均未观察到治疗的不良反应。
含有FGLM-酰胺和IGF-1的眼药水可促使神经营养性角膜病变患者的持续性上皮缺损快速修复。
